Category Archives: Press Release

Healthcare Mobility Solutions Market Will Likely to Expand at a Steady CAGR of 25.50% by 2023

The competitive landscape in the healthcare mobility solutions market is highly fragmented due a large number of players. Transparency Market Research has identified McKesson Corporation, Cerner Corporation, and Philips Healthcare as the key players in this market as of 2014. “These players have a strong presence across Europe and North America,” reports the author of this research report.

To increase their geographical reach leading companies are also trying to expand their focus on inorganic expansion. For instance, Cerner Corporation joined hands with Truman Medical Centers (TMC) to collectively work with healthcare information technology to offer better care to patients and improved solutions to the medical fraternity.

Read Report Overview: https://www.transparencymarketresearch.com/healthcare-mobility-solutions-market.html

Penetration of Smartphones Encourages Adoption of Healthcare Mobility Solutions

The incorporation of multiple application platforms in new-age smartphones has made tech savvy users opt for medical attention through their personal digital assistants. The gap between the need of the patients and the medical help is being blurred by mobile applications that have improved response time, clinician decision making, and overall patient care.

The strong year-on-year increase in the penetration of smartphones and the accessibility to the Internet has thereby increased the deployment of healthcare mobility solutions. Furthermore, the growing acceptance of healthcare mobile solutions such as enterprise mobility platforms, mobile applications, and mobile devices is adding value to the efficiency and effectiveness of healthcare in remote areas.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4773

Wireless Technologies Promote Usage of Healthcare Solutions

The healthcare mobility solutions market is also being fueled by the successful rollout of wireless technologies such as 3G, LTE-A, and LTE. The wide network of these advanced technologies that deliver high-speed, seamless connectivity, and effortless communication has allowed vendors in this market to offer groundbreaking healthcare solutions. The prompt two-way response between the medical professional and patient to save lives has only been possible due to the efficient rollout of LTE and LTE-A. This market will also be driven by the declining nursing staff and the shortage of centers to treat the ever-growing pool of patients.

However, developing regions of Latin America and Asia Pacific are expected to be attractive markets for these solutions. The unmet medical needs of patients across China, Brazil, South Africa, and India will not only offer a huge potential for growth to the companies operating in this market but also revolutionize the state of medical care in these regions. The soaring patient pool, increasing number of geriatrics, and the abnormal doctor-to-patient ratio are all expected to drive the demand for IT-enabled healthcare solutions in these regions.

Buy Healthcare Mobility Solutions Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=4773&ltype=S

Risk of Data Hacking and Identity Theft Prevents Market to Reach Full Potential

The issues faced in complete acceptance of healthcare mobility solutions are a threat to private information and security breaches. The potential risk of data hacking, identity theft, unauthorized access, and tampering with patient data is making both the medical fraternity as well as the patients skeptical about relying on these solutions.

Asia Pacific to Rise at Fastest CAGR

According to the research report, the global healthcare mobility solutions market was valued at US$20.13 bn in 2014 and is expected to reach US$148.66 bn by the end of 2023. During the forecast period of 2015 and 2023, the overall market will progress at a pace of 25.5% CAGR. The leading segment in the overall market will be mHealth application segment as analysts predict it will expand at a whopping CAGR of 25.6% during the forecast period. Geographically, Asia Pacific is expected to be the fastest growing segment due to a huge population base. This regional segment will grow at an impressive CAGR of 28.3%.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Advertisements

Glycobiology Market Estimated to Experience a Hike in Growth by 2024

Global Glycobiology Market: Snapshot

The world glycobiology market is envisioned to sense a strong lead in the biotechnology sector with the mutual advantage of glycobiology and proteomics proliferating their applications in different fields. Due to the capacious overlap and interdependency of both glycobiology and proteomics markets on the part of instrument sections, the global market could gain a sound impetus from the episode.

With regard to segmentation, the global glycobiology market could be analyzed on the basis of product, application, and end user. The geographical segmentation can provide an outlook of the key regions that practice the various applications of glycobiology.

Read Report Overview: http://www.transparencymarketresearch.com/glycobiology-market.html

The authors of the report have taken to thoroughgoing primary and secondary research to provide a reliable platform for both new entrants and established players to make intelligent decisions. Besides this, the analysts have provided critical data on the forecast of future trends and present market size.

Global Glycobiology Market: Trends

The international glycobiology market is foreseen to be motivated by the enlarging research and development spending on the part of biotechnology and pharmaceutical organizations. One of the most influential motive powers for the growth of the global market is the heightening private and government funding initiated for forwarding research activities related to proteomics and glycomics.

The drug discovery and development division by application was anticipated to hold a gargantuan share in the world glycobiology market in 2016. The advancement of this possible segment could be accredited to the rise in the evolution of unconventional therapies and drugs through thorough research and development. Other segments such as immunology, oncology, and diagnostics could be listed under the application category.

Out of the many probable product type segments, enzymes are predicted to register a higher CAGR and growth on the back of their extensive applications in drug discovery and research and development operations. While they can be further segregated as sialyltransferases, neuraminidases, glycosyltransferases, and glycosidases, the other glycobiology products could be reagents, kits, and instruments.

Download Brochure of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19844

If the end users are concerned, a larger share of the global glycobiology market was expected to be secured by academic research institutes in 2016. The success of this end-user segment could be attributed to the strong private and government support offered through funding. Other end users such as contract research organizations and pharmaceutical and biotechnology firms are foretold to stay in the run.

Global Glycobiology Market: Geography

Although the world glycobiology market could be geographically divided into North America, Europe, Asia Pacific, and Rest of the World, Asia Pacific is envisaged to outshine while riding on a sharp CAGR. Much of the demand for glycobiology in Asia Pacific could be ascribed to the uprising significance of companion diagnostics, maturing want for customized medicine, and escalating research and development commercialization by biotech and pharma firms.

North America may not lag behind in terms of growth, mainly due to the increasing incidences of herpes, AIDS, cancer, and other infectious and chronic illnesses. The sedentary lifestyle and multiplying geriatric population in this region is deemed to be responsible for the prevalence of such diseases. Moreover, citizens are being able to access well-assembled reimbursement programs and afford expensive medication, which is expected to further push the rise of North America.

Pre Book Glycobiology Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=19844&ltype=S

Global Glycobiology Market: Competition

The report presented here for the perusal of the buyers could include an unfathomable study of the competitive landscape along with the future trends of the glycobiology industry. Some of the epoch-making players of the world glycobiology market could be Waters Corporation, Thermo Fisher Scientific, Takara Bio, Inc., Merck KGaA, Shimadzu Corporation, ProZyme, Inc., New England Biolabs, Danaher Corporation, Bruker Corporation, and Agilent Technologies.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Typhoid Vaccines Market Expansion Projected to Gain an Uptick During 2017 – 2025

Typhoid is a bacterial infection that can lead to diarrhea, high fever, and vomiting. It can be fatal if not treated properly. It is caused by the bacterium Salmonella typhi. The disease is more prevalent in low-income countries, as basic prevention strategies such as good hygiene practices and access to clean water are not available in these countries. However, the spread of the disease in low-income countries is preventable. Every year, around 5,700 cases are reported only in the U.S., out of which 75% occur while traveling overseas. Globally, around 21.5 million people contract typhoid every year. Typhoid can be treated with antibiotics. However, vaccination is more effective for eradicating typhoid, as typhoid vaccines is beneficial in two ways, one by providing protection to vaccinated individual and two, by providing herd immunity indirectly to unvaccinated individuals when the vaccination is carried out on a large scale.

Read Report Overview: https://www.transparencymarketresearch.com/typhoid-vaccines-market.html

The global typhoid vaccines market can be segmented in terms of product, mode of administration, distribution channel, and end-user. In terms of product, typhoid vaccines are of four types viz. Ty21a, Vi capsular polysaccharide vaccine, Vi Conjugate (Vi-TT), and Vi Conjugate (Vi-REPA). Ty21a is a live vaccine and Vi capsular polysaccharide is a sub-unit vaccine. The other two types are restricted to the private sector and they do not have global acceptance. For instance, Vi Conjugate (Vi-TT) is licensed only for the market in India. Based on mode of administration, the typhoid vaccines market can be segmented into oral or injectable. For instance, Ty21a is taken orally, while Vi capsular polysaccharide vaccine is injectable. Based on distribution channel, the typhoid vaccines market can be classified into hospitals, pharmacies, and clinics / health care centers associated with government programs. The inflow of patients to hospitals is expected to increase during the forecast period, as hospitals are considered to be more reliable and they have a large number of suppliers, reimbursement authority, and government support. Based on end-user, the typhoid vaccines market has been segmented into pediatrics and adults.

The typhoid vaccines market is driven by several factors such as increasing government initiatives, rising prevalence of typhoid, growing immunization campaigns across the globe, rising initiatives by non-government organizations for vaccination, and increasing investments by companies in vaccine development. Increased research on typhoid vaccine in the emerging market have opened an array of growth opportunities for the typhoid vaccines market. However, less availability of typhoid vaccines in remote areas and strict regulatory measures are expected to restrain the market from 2017 to 2025.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37556

Based on geography, the global typhoid vaccines market has been divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the major share of the typhoid vaccines market in terms of revenue in 2016. This is attributable to increasing awareness among people in the region, which leads to the rise in demand for vaccination to infants, children, and adults. Also, easy availability of vaccines in the U.S. and favorable government initiatives for vaccination programs fuel the typhoid vaccines market in the region. The market for typhoid vaccines in Asia Pacific is expected to expand at the maximum CAGR during the forecast period, due to government initiatives for immunization against typhoid and large population base, especially in China and India. China is likely to lead the Asia Pacific typhoid vaccines market during the forecast period, owing to increase in government support for vaccination and rise in the number of people with typhoid disease in the region. Brazil is likely to be a prominent market for typhoid vaccines in Latin America by 2025. The developing health care infrastructure and interest of key players in investing in Brazil by establishing manufacturing units in the region are major factors driving the typhoid vaccines market in Brazil. GCC dominates the typhoid vaccines market in the Middle East, whereas, South Africa holds the leading share of the market in Africa. The typhoid vaccines market in Africa is experiencing strong growth, due to rapid rise in vaccination programs, frequent typhoid outbreaks in the region, and increasing investments by major players.

Key players operating in the global typhoid vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi, and Johnson & Johnson.

Pre Book Typhoid Vaccines Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=37556&ltype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Antacids Market to Report a CAGR of 3.7% Between 2017 and 2025

With a large pool of established players such as AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble, Reckitt Benckiser Group plc, Sanofi, Sun Pharmaceuticals Ltd., Takeda Pharmaceutical Company Ltd., and Valeant Pharmaceuticals International Inc., the worldwide antacids market features a competitive and a fragmented vendor landscape, notes a research report by Transparency Market Research (TMR).

Development of novel therapies and new formulations of existing drugs is what leading players in this market are concentrating on to gain competitive advantage. Other key growth strategies adopted by key players include strategic acquisitions, collaborations, and partnerships that will not only help them expand their geographical presence but will help strengthen their business position as well.

Read Report Overview: https://www.transparencymarketresearch.com/antacids-market.html

As per estimates of a report by TMR, the global antacids market will clock a 3.7% CAGR between 2017 and 2025 to reach a valuation of US$18.7 bn by 2025 end. Proton pump inhibitors stood as the leading drug class segment in 2016 and the trend is anticipated to continue over the forecast period. The others distribution channel that constitutes online pharmacy and online drug store led the overall market in 2016. Rising popularity of e-commerce and surge in the number of online medicine providers are estimated to positively impact the segment’s expansion. Geography-wise, Europe emerged as the most lucrative market for antacids in 2016 due to the rising incidence of gastro esophageal reflux diseases.

Growing Geriatric Population More Susceptible to Acid Reflux Positively Influences Market

“Considering the changing dietary habits and growing geriatric population worldwide, the global antacids market is anticipated to be on the rise in the upcoming years,” explains a TMR analyst. As per statistics of the Asian Development Bank, the population of individuals above the age of 60 years in Asia is projected to touch 923 million by 2050. The elderly population that is more susceptible to gastroesophageal reflux diseases (GERD) and peptic ulcers is anticipated to account for significant demand for antacids in the region. The intake of medication for other medical conditions, which are associated with acid reflux and excess acid production, also account for significant demand for antacids among this population. Further, as per statistics by the World Bank, Japan recorded the highest proportion of geriatric population in 2014; 25% population was above the age of 65 years and above in the same year. This is acting in favor of the growth of Asia Pacific antacids market.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32864

Apart from this, the increasing incidence of heartburn, acidity, and gastro esophageal reflux diseases, and changing lifestyle are stoking growth of the worldwide market for antacids. For instance, according to a study published in Gut (BMJ journal), the prevalence of GERD in Europe ranges from 8.8% – 25.9%. Countries in Northern Europe account for a high prevalence of gastro intestinal and gastro esophageal diseases over countries in Southern Europe.

Self-medication is a common practice for occasional heartburn and acidity and the easy availability of antacids over the counter is also having a positive influence on the market’s growth. This is because antacids suppress the stomach acid either by neutralizing it or by inhibiting the acid production in stomach.

Buy Antacids Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=32864&ltype=S

Risk of Side Effects May Impede Growth

However, on the flip side, prolonged use of proton pump inhibitors are associated with serious side effects such as kidney failure. The availability of generics in emerging and underdeveloped markets and over-reliance on over the counter drugs are inhibiting the market’s expansion in these regions.

 

Renal Denervation Devices Market to Observe Strong Development by 2021

Renal denervation is a minimal invasive procedure used for the treatment of drug resistant or treatment resistant hypertension. This procedure reduces blood pressure by ablation of renal nerves. With rising incidences of uncontrolled and treatment resistant hypertension, demand for RDN devices is expected to grow in future. Benefits of the RDN procedure such as shorter treatment time and permanent effects over drug treatment, which indirectly reduces the cost of treatment, will also accelerate the market growth. Furthermore, increasing awareness of the RDN process and expected approvals from regulatory bodies such as FDA will boost the demand for RDN devices globally.

Read Report Overview: http://www.transparencymarketresearch.com/renal-denervation-devices-market.html

WHO estimates indicate that in 2012 more than 1.2 billion people were suffering from hypertension. Clinical data collected from various regions shows the global prevalence of hypertension to be about 38% to 45%. Moreover, new data released by National Health and Nutrition Examination Survey (NHANES) indicates the occurrence of hypertension in the US to be around 30%. After studying data from various clinical studies it is observed that more than 25% to 45% of hypertensive people suffer from uncontrolled hypertension and 15% of these people are observed to have treatment resistant hypertension. This represents a positive outlook for RDN procedure as it considerably reduces the blood pressure in patients with treatment resistant hypertension, thus providing a huge basis for growth of the market.

Europe is the largest as well as fastest growing regional market for RDN devices followed by Asia-Pacific. Europe is expected to maintain its dominating position with a strong double digit growth through 2021. The RDN devices market in North America is expected to accelerate due to FDA approvals in the next 4-5 years coupled with the high incidence of lifestyle-related cardiovascular diseases in the region. Aging population along with a high incidence of diabetes will boost the demand for RDN devices in Asia-Pacific, which is estimated to have a large percentage of population that has not even been diagnosed. Large numbers of hypertensive people have not yet been diagnosed with uncontrolled hypertension globally and are still trying many alternate therapies and medications and struggling to control hypertension.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=400

Due to insufficient clinical data, market players are currently struggling to get approvals from regulatory bodies. However, some leading players have received certification by adding innovation to their products coupled with strong research and development activities. Currently, only five devices have received approval for CE mark certification which includes Medtronic’s Symplicity, Boston Scientific’s (Vessix Vascular) V2, St. Jude’s EnligHTN, Covidien’s OneShot and ReCor Medical’s Paradise with not a single RDN therapy receiving approval from the US FDA. Medtronic is the leading player in the RDN devices market and contributes for more than 85% of the global market share. ReCor Medical Paradise is the only ultrasound denervation system that has CE certification. However, in the coming years, a high threat of new entrants is expected with innovative technologies which will reduce procedure time and have greater efficacy. Yet with all the challenges, the renal denervation procedure is considered a boon to treatment of uncontrolled hypertension and thus, the market growth in coming years is expected to be very strong.

Buy Renal Denervation Devices Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=400&ltype=S